Study shows CAR T-cell therapy’s risk of second primary malignancies comparable to other treatments

Neuronetics said the FDA cleared its transcranial magnetic stimulation (TMS) device, NeuroStar, as an adjunct therapy for the first-line treatment of major depressive disorder in

Clin­i­cal-stage neu­ro­science biotech Rap­port Ther­a­peu­tics will seek about $122 mil­lion in net pro­ceeds from its ini­tial pub­lic of­fer­ing, ac­cord­ing to new se­cu­ri­ties pa­per­work out­lin­ing its